Galsulfase
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Galsulfase
- Galsulfase: From Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome) to Ptosis-Strabismus-Ectopic Pupils Syndrome
Galsulfase: From Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome) to Ptosis-Strabismus-Ectopic Pupils Syndrome
Note: The evidence pack’s taiwan_regulatory.licenses and drug.original_indications are empty, and original_moa is flagged as a data gap (DG002). The original indication/MOA above is reconstructed from the mechanistic annotation embedded in this same evidence pack (rank-10 rationale, which identifies galsulfase as N‑acetylgalactosamine‑4‑sulfatase used for MPS VI), not from an independent source.
One-Sentence Summary
Galsulfase (DrugBank DB01279) is an enzyme replacement therapy whose target enzyme, per this evidence pack, is used in Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome); the drug is currently not marketed in Taiwan. The TxGNN model’s top-ranked prediction is Ptosis-Strabismus-Ectopic Pupils Syndrome, but this pairing has 0 clinical trials and 0 publications, and the model’s own rationale states there is no known mechanistic link.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Ptosis-Strabismus-Ectopic Pupils Syndrome |
| TxGNN Prediction Score | 97.89% (model rank 17,520) |
| Evidence Level | L5 (model prediction only) |
| Market Status (Taiwan) | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
The evidence pack does not provide a confirmed original_moa field for galsulfase (flagged as data gap DG002, severity High). However, the rationale attached to this drug’s own predictions (specifically the rank-10 candidate) identifies galsulfase as N-acetylgalactosamine-4-sulfatase, an enzyme-replacement therapy for Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome), acting via chondroitin/dermatan sulfate metabolism.
For the top-ranked candidate, Ptosis-Strabismus-Ectopic Pupils Syndrome, the evidence pack’s own mechanistic assessment is explicit and negative: this is a rare congenital ocular structural/neurodevelopmental syndrome with no known connection to galsulfase’s sulfate-metabolizing enzyme-replacement mechanism. The pack states this pairing reflects “TxGNN embedding similarity only, with no mechanistic plausibility support” — i.e., the prediction is driven by graph-embedding proximity rather than any biological rationale.
By contrast, the same evidence pack’s rank-10 candidate, Scheie syndrome, is at least in the correct disease family (a mucopolysaccharidosis), though it targets a different enzyme deficiency (MPS I / α-L-iduronidase, treated with laronidase) than galsulfase’s actual target (MPS VI). That candidate has some literature support (see below) but is not the top-ranked prediction and was not selected as this report’s primary subject.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Detailed safety information (key warnings, contraindications, drug interactions) is not currently available in this evidence pack. TFDA labeling data was queried but is a blocking data gap (DG001). Please refer to the manufacturer’s official product labeling once available.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Ptosis-Strabismus-Ectopic Pupils Syndrome) has no clinical trials, no literature, and the model’s own rationale explicitly disclaims any mechanistic link — this is a pure embedding-similarity artifact (L5), not a biologically grounded repurposing hypothesis.
To proceed, the following is needed:
- TFDA label/warnings and contraindications (DG001, Blocking) — required before any S1 safety screening
- Confirmed mechanism of action for galsulfase from DrugBank (DG002, High)
- A biologically plausible rationale connecting galsulfase’s sulfatase-replacement mechanism to this specific ocular/neurodevelopmental syndrome, or reprioritization toward a mechanistically closer candidate (e.g., rank-10 Scheie syndrome, which at least sits within the mucopolysaccharidosis disease family, despite targeting a different enzyme deficiency than galsulfase)
- Confirmation of Taiwan market status before any regulatory pathway planning, since the drug currently holds zero local authorizations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.